Drug Approval | September 23, 2024
Bavarian Nordic receives EMA approval of mpox vaccine for adolescents
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
The patient has been isolated in a designated hospital and is currently stable
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
Subscribe To Our Newsletter & Stay Updated
